MaxCyte raises 2026 revenue guidance on preliminary third-quarter results
The cell-engineering company said third-quarter core business revenue rose 26% year over year, pushing full-year guidance to approximately $34 million.
MaxCyte, Inc. announced on October 14, 2026 preliminary, unaudited revenue figures for the third quarter ended September 30, 2026 and raised its full-year revenue guidance. The company said core business revenue came in at approximately $8.1 million in the third quarter of 2026, a 26% increase compared to the third quarter of 2025.1 It also reported Strategic Platform License Program-related revenue of more than $1.0 million, including a $1.0 million milestone payment received in the quarter.1 Royalty revenue will be disclosed separately when MaxCyte reports full financial results on November 10, 2026, as the company plans to report royalty revenue alongside its full financial results on that date.1
For the full year, MaxCyte now expects total revenue of approximately $34 million, up from prior guidance of $30 million to $32 million, with core business revenue of approximately $28 million versus a prior range of $25 million to $27 million.1 The company also raised its SPL-related outlook, saying it now expects approximately $6 million in SPL Program-related revenue for the year, versus prior guidance of about $5 million, split between roughly $4 million in milestone payments and about $2 million in commercial royalties.1
CEO Maher Masoud attributed the quarter's results in part to timing, saying the company anticipated returning to growth in the second half of 2026 and saw outperformance in the third quarter driven by accelerated instrument purchasing from a large customer that had originally been expected in the fourth quarter.1 He added that the SPL guidance increase followed recognition of a milestone from one of the company's SPL partners, the second such milestone achieved in 2026.1 On the partnered pipeline, Masoud said MaxCyte is now supporting more late-stage clinical programs under its SPL partnerships than ever before, including two pivotal trials with potential for approval as early as 2027.1
The preliminary figures are subject to change, as the results are preliminary and unaudited pending completion of MaxCyte's quarterly closing and review procedures, and may differ from the final figures in its consolidated financial statements.1 MaxCyte will hold its third-quarter earnings call on November 10, 2026.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.